SPIA
GLMD icon

Steward Partners Investment Advisory’s Galmed Pharmaceuticals GLMD Stock Holding History

Steward Partners Investment Advisory’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$1K – 3228
2021
Q3 		$1K Hold
3
– – ﹤0.01% 3072
2021
Q2 		$2K Hold
3
– – ﹤0.01% 6868
2021
Q1 		$1.72K Buy
+3
New +$2.08K ﹤0.01% 3253

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Partners Investment Advisory's GLMD Position: Q4 2021 in Review

Steward Partners Investment Advisory sold out of Galmed Pharmaceuticals (GLMD) in Q4 2021, closing a stake of 3 shares — an estimated $1K sold.

Steward Partners Investment Advisory first reported a position in GLMD in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q2 2021. 24 funds tracked by Wall St. Rank hold GLMD as of Q4 2021.

  • Steward Partners Investment Advisory reported no remaining Galmed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 3 Galmed Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Steward Partners Investment Advisory first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Steward Partners Investment Advisory's Galmed Pharmaceuticals position peaked at $2K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2021, filed 8 Feb 2022.